Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversidad Autonoma de Nuevo Leon

About this trial

Dry eye syndrome is a common eye disease that affects 1 to 2 out of 10 persons around the planet. One common cause of this disease is the meibomian gland dysfunction. Meibomian glands are very small glands located at the rim of the eyelids that produce an oily substance that prevents the evaporation of tears. When these glands are compromised, the tear film evaporates quickly and the eyes dry up. This disease presents as eye irritation, foreign body sensation, inflammation, etc. The treatment of choice for MGD is eyelid massage and warm compresses 2 times a day. However, these treatments not always work perfectly, and as a result, patients find it hard to follow doctor's orders. Another kind of treatment is thermal therapy. There are several devices that are designed to apply heat on the eyelids, such as Lipiflow, MiBo Thermoflo, and Blephasteam. In this study, we want to find out whether thermal therapy with MiBo Thermoflo works better than warm compresses and eyelid massage use in the treatment of dry eye caused by MGD. To do this, we will select several patients and will assign them randomly to either the group with thermal therapy with MiBo Thermoflo or to the group with warm compresses and eyelid massage. The Mibo group will receive 3 sessions of thermal therapy at 2 weeks interval and the control group warm compresses and eyelid massage 2 times per day. All subjects will have a follow up of 24 weeks and we will compare results for both groups at the end of the study.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Dry eye syndrome with meibomian gland dysfunction alone or in combination of other type of dry eye.

Patients who were previously treated with eyelid massages and warm compresses without any improvement.

Disqualifiers

Pregnant women.

History of ocular surgery within three months prior to inclusion.

History of trauma, infection or inflammation within three months prior to inclusion.

Contact lens use in the last week before inclusion.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Mibo Thermoflo

    Device

    Thermal therapy with Mibo Thermoflo for 11 minutes per eye, during each session.

  • Warm compresses and eyelid massage

    Other intervention

    Warm compresses plus eyelid massage 2 times per day 11 minutes per eye.

Treatment groups

42 Participants
are divided into 2 treatment groups
Group A: Mibo Thermoflo (thermal device)Experimental treatment 1 intervention
Group B: Warm compresses and eyelid massageActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Meibomian gland expressibility

Changes in meibomian gland structure will be evaluated by meibomian gland expressibility.

Time frame
Basal to 24 weeks
2

Meibum quality

Changes in meibomian gland structure will be evaluated with the meibum quality in slit lamp graded as: clear, opaque, granular and toothpaste for meibum worst secretion.

Time frame
Basal to 24 weeks
3

Corneal and conjunctival staining with fluorescein dye

Ocular surface damage will be graded with corneal and conjunctival staining with fluorescein dye.

Time frame
Basal to 24 weeks
4

Corneal and conjunctival staining with lissamine green dye

Ocular surface damage will be graded with corneal and conjunctival staining with lissamine green dye.

Time frame
Basal to 24 weeks

Secondary outcomes

1

Short term changes with corneal and conjunctival staining with fluorescein dye

Short term changes in ocular surface damage will be graded with corneal and conjunctival staining with fluorescein dye.

Time frame
These parameters will be evaluated before sessions of termal therapy at week 2 and week 4
2

Short term changes with corneal and conjunctival staining with lissamine green dye

Short term changes in ocular surface damage will be graded with corneal and conjunctival staining with lissamine green dye.

Time frame
These parameters will be evaluated before sessions of termal therapy at week 2 and week 4
3

Short term changes in tear stability

Short term changes in tear stability will be measured with Tear Break-up Time (TBUT). A result \>10 seconds will be considered normal, a result \<10 seconds will be considered pathological.

Time frame
These parameterd will be evaluated before sessions of termal therapy at week 2 and week 4
4

Short term changes in Symptom Assessment in Dry Eye questionnaire (SANDE)

Short term changes in ocular surface symptoms will be assessed by the Symptom Assessment in Dry Eye (SANDE). The SANDE questionnaire has two questions presented in a visual scale. The two questions assess the frequency and severity of dry eye symptoms. A less rate prove changes in ocular surface symptoms and quality of life improvement.

Time frame
These parameters will be evaluated before sessions of termal therapy at week 2 and week 4

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Universidad Autonoma de Nuevo Leon

Lead sponsor

Hospital Universitario Dr. Jose E. Gonzalez

Collaborator